8-K: Precision BioSciences Announces Hepatitis B Gene Editing Data

Precision BioSciences presented new clinical data from its PBGENE-HBV trial at EASL 2026, showing direct elimination of cccDNA in chronic hepatitis B patients.

Summary

• Precision BioSciences announced new clinical data from its ongoing Phase 1 ELIMINATE-B trial for PBGENE-HBV, a gene editing therapy for chronic hepatitis B.
• The data, presented at the European Association for the Study of the Liver (EASL) Congress 2026, demonstrate that PBGENE-HBV directly eliminates cccDNA, the viral source.
• Biopsy data showed a 1-log (10-fold) reduction in cccDNA-derived transcripts through cccDNA elimination, with remaining cccDNA inactivated by indels.
• pgRNA was established as a biomarker, showing loss in 100% of patients with detectable pgRNA at baseline, correlating with cccDNA elimination.
• PBGENE-HBV demonstrated a manageable safety profile with no dose-limiting toxicities observed across 38 doses in 16 patients.
• Common adverse events were infusion-related reactions, and transient Grade 3 ALT/AST abnormalities were observed but were asymptomatic.
• Mitigation protocols for hypotension have been implemented, and no Grade 3 hypotension or LNP-related ALT/AST abnormalities have occurred since.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to strong clinical data demonstrating a novel mechanism of action and a clear path towards a potential cure for chronic hepatitis B, despite some manageable safety concerns.

Positives

• New biopsy data demonstrate direct elimination of cccDNA by PBGENE-HBV, a key mechanism for viral cure.
• A 1-log (10-fold) reduction in cccDNA-derived transcripts was observed.
• Remaining cccDNA was permanently inactivated by indels, knocking out polymerase function.
• pgRNA loss was achieved in 100% of patients with detectable pgRNA at baseline, confirming cccDNA editing.
• 100% of patients (n=15) experienced substantial HBsAg declines, indicating broad antiviral activity.
• PBGENE-HBV has a well-characterized and manageable safety profile with no dose-limiting toxicities.
• Mitigation strategies for hypotension have been successfully implemented, preventing further Grade 3 events.

Negatives

• Grade 3 hypotension was observed during dose escalation, with one patient experiencing two serious adverse events (SAEs) deemed treatment-related.
• Transient Grade 3 reversible ALT/AST lab abnormalities have been observed, although asymptomatic.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other important factors that could cause actual results to differ materially.
• The company's ability to advance product candidates into, and successfully design, implement, and complete, clinical trials.
• Potential manufacturing problems associated with the development or commercialization of any product candidates.
• Delays or difficulties in enrolling patients in clinical trials.
• The risk that other genome-editing technologies may provide significant advantages over the ARCUS technology.
• Potential litigation related to infringement or misappropriation of intellectual property rights.

Future Outlook

The company expects to treat more patients in Part 1 of the ELIMINATE-B trial to strengthen the data set and collect additional biopsy data. Precision is working with global investigators to establish a framework for nucleoside analog withdrawal and expansion into Part 2 of the trial. The current and future data are expected to inform the selection of the optimal dosing schedule for Part 2. Additional updates on the ELIMINATE-B trial are expected by the end of 2026.

Management Comments

• "The data we are presenting today represent a transformational step forward in the hepatitis B field, as we now have the first data in patients supporting the ability of PBGENE-HBV to directly target and eliminate cccDNA driving viral destruction."
• "We believe these data indicate that hepatitis B may be approaching a turning point where chronic care moves from lifelong suppression of an active virus toward a finite, biomarker-guided complete viral cure."
• "There has never been a treatment that could directly target and eliminate the root source of hepatitis B viral replication and now there is."
• "The elimination mechanism of action for PBGENE-HBV directly aligns with the current FDA guidance that eradication of HBV DNA is the optimal endpoint for approval."
• "As we expand enrollment in the trial and advance toward the next phase, we look forward to providing additional updates building on these encouraging data results."
• "This exciting biopsy data from the ELIMINATE-B trial represents a first for the field. Now that we have evidence that PBGENE-HBV is eliminating cccDNA as designed and has a clear therapeutic window, I look forward to finishing the dose and schedule optimization, stopping nucleoside analog treatment and testing for viral cure."

Industry Context

StockSavvy.ai notes that Precision BioSciences' announcement positions PBGENE-HBV as a potentially curative therapy for chronic hepatitis B, a significant advancement over current treatments that focus on lifelong viral suppression. The establishment of cccDNA elimination and pgRNA loss as key indicators aligns with FDA's guidance for an optimal endpoint, potentially accelerating development and approval pathways in a field with high unmet need.

Stakeholder Impact

• Shareholders: Positive impact expected from promising clinical data that could lead to a breakthrough therapy and potential market leadership in chronic hepatitis B treatment.
• Patients: Potential for a curative treatment for chronic hepatitis B, moving beyond lifelong viral suppression to a finite cure.
• Healthcare Providers: Introduction of a novel therapeutic approach that directly targets the root cause of hepatitis B, potentially simplifying treatment paradigms.

Next Steps

• Treat more patients in Part 1 of the ELIMINATE-B trial to increase the size and strength of the data set.
• Collect additional biopsy data to support the direct targeting and elimination of cccDNA.
• Work with global investigators to create the future framework for nucleoside analog withdrawal.
• Expand into Part 2 of the ELIMINATE-B trial.
• Inform selection of the optimal dosing schedule for Part 2 expansion based on current and future data.
• Provide additional updates on the ELIMINATE-B trial by the end of 2026.

Key Dates

Recommendation

The data presented are highly encouraging, demonstrating a novel mechanism of action and potential for a curative therapy. However, the trial is still in Phase 1, and further data, particularly from larger patient cohorts and Part 2 of the trial, are needed to confirm efficacy, long-term safety, and durability. The company also faces ongoing risks associated with clinical development and capital requirements. Therefore, a 'hold' recommendation is appropriate pending further de-risking events.

Keywords

Precision BioSciences, PBGENE-HBV, Hepatitis B, Gene Editing, cccDNA, ELIMINATE-B trial, ARCUS platform, EASL Congress